Med Ed Report briefs: February 2013

Share this article:
Lisa Keilty
Lisa Keilty

The economic crisis in Spain is affecting pharma funding for CME, says WentzMiller Global Services. It remains to be seen how declining government reimbursement rates in the EU will affect pharma spending for professional education, the consulting firm noted in its Dec. 2012-Jan. 2013 newsletter.

Meeting support firm Plannernet started a compliance division, PMC2. It will be led by new hire Lisa Keilty, CMP, who during her 10 years at Pfizer built its international meeting organization. She then started her own firm. In her new role, Keilty will seek to apply her knowledge of regulations to safeguard client compliance.

Physician social network QuantiaMD promoted Mike Coyne from president to CEO, and appointed Daniel Malloy as SVP, the firm said. Eric Schultz, QuantiaMD's founder and current CEO, moves to executive chairman.

Meeting Professionals International (MPI) said it was awarded a two-year agreement to co-develop sessions at the World Congress Global Medical Meetings Summit, taking place on February 28- March 1, in Philadelphia. MPI is also moderating a panel set to include meetings professionals from Daiichi Sankyo and Novartis.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?